辛伐他汀治疗早期糖尿病肾病患者的临床研究  

Clinical trial of simvastatin in the treatment of patients with early diabetic nephropathy

作　　者：盛丹虹 邵国民 SHENG Dan-hong;SHAO Guo-min(Department of Nephrology,First People*5 Hospital of Hangzhou Fuyang District,Hangzhou 311404,Zhejiang Province,China)

机构地区：[1]杭州市富阳区第一人民医院肾内科,浙江杭州311400

出　　处：《中国临床药理学杂志》2020年第7期760-762,共3页The Chinese Journal of Clinical Pharmacology

摘　　要：目的观察辛伐他汀对早期糖尿病肾病(DN)患者转化生长因子-β1(TGF-β1)、组织金属蛋白酶抑制物-1(TIMP-1)及肾功能的影响。方法将我院肾病科收治的104例DN患者随机分为试验组52例和对照组52例。对照组用常规治疗方法。试验组在对照组治疗的基础上,给予辛伐他汀,每次20 mg,每天3次。2组均连续治疗4周。比较治疗前后2组患者的TGF-β1、TIMP-1、血糖和肾功能。结果治疗后,试验组和对照组尿蛋白分别为(10.18±4.03)和(15.03±4.36)mg·L-1,β2微球蛋白分别为(2.27±0.87)和(3.01±1.11)mg·L-1,尿白蛋白排泄率分别为(17.65±7.32)和(22.97±7.77)μg·min-1,TIMP-1分别为(69.34±12.21)和(101.45±10.84)ng·mL-1,TGF-β1分别为(111.03±11.33)和(144.23±14.02)ng·mL-1,空腹血糖分别为(5.28±0.21)和(5.67±0.42)mmol·L-1,餐后2 h血糖分别为(6.74±0.57)和(7.02±0.72)mmol·L-1,差异均有统计学意义(均P<0.05)。试验组和对照组的药物不良反应发生率分别为9.62%和13.46%,差异无统计学意义(P>0.05)。结论辛伐他汀可有效降低DN患者血糖含量,改善肾组织纤维化,促进肾功能恢复。Objective To explore the effects of simvastatin on transforming growth factor β 1(TGF-β1), tissue inhibitor of metalloproteinase-1(TIMP-1) and renal function in patients with early diabetic nephropathy(DN).Methods A total of 104 patients with DN treated in the endocrine department of our hospital were randomly divided into treatment group(n=52) and control group(n=52).Control group was treated with routine method.Treatment group was treated with simvastatin 20 mg, three times a day on the basis of control group.All patients were treated for 4 weeks.The levels of TGF-β1, TIMP-1, blood glucose and renal function were compared between the two groups.Results After treatment, the levels of urinary protein in treatment group and control grouo were(10.18±4.03),(15.03±4.36) mg·L-1, β 2 microglobulin were(2.27±0.87),(3.01±1.11) mg·L-1, urinary albumin excretion rates were(17.65±7.32),(22.97±7.77) μg·min-1, TIMP-1 were(69.34±12.21),(101.45±10.84)ng·mL-1, TGF-β1 were(111.03±11.33),(144.23±14.02) ng·mL-1, fasting blood glucose were(5.28±0.21),(5.67±0.42) mmol · L-1,2 h postprandial blood glucose were(6.74±0.57),(7.02±0.72) mmol·L-1,all with significant difference(all P < 0.05).The incidence rates of adverse drug reactions in treatment group and control group were 9.62%,13.46%,without significant difference(P>0.05).Conclusion Simvastatin can effectively reduce the blood sugar content in patients with DN,improve renal fibrosis and promote the recovery of renal function.

关 键 词：糖尿病肾病 辛伐他汀 转化生长因子-Β1 组织金属蛋白酶抑制物-1 血糖 肾功能 

分 类 号：R972.6[医药卫生—药品]